VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC

被引:6
作者
Zhang, Mi [1 ]
Zhang, Juan [1 ]
Liu, Na [1 ]
Wang, Biyuan [1 ]
Zhou, Yan [1 ]
Yang, Jin [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
VISTA; triple-negative breast cancer (TNBC); prognosis; immune infiltration; M1; macrophages; ACQUIRED-RESISTANCE; CHECKPOINT; THERAPY;
D O I
10.3389/fonc.2022.961374
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundV-domain Ig-containing suppressor of T cell activation (VISTA), a critical immune checkpoint protein, can regulate the immune system. Nevertheless, little information is available on the expression level of VISTA and its clinical significance as well. The immunological and prognostic role of VISTA in triple-negative breast cancer (TNBC) still remains unclear. MethodsThe clinical significance and expression of VISTA in TNBC were examined using RNA sequencing and clinical data. Cancer single-cell state atlas (CancerSEA), gene set enrichment analyses (GSEA), single sample GSEA, ESTIMATE algorithm, immunohistochemistry (IHC) were utilized to assess the functions of VISTA. ResultsVISTA was down-regulated and closely associated with good prognosis in TNBC. The expression of VISTA was higher in Immunity-H group and immunomodulatory (IM) subtype. The level of VISTA expression in TNBC gradually increased with the degree of stromal tumor infiltrating lymphocytes (sTILs) infiltration. In addition, the high expression of VISTA was strongly linked to higher proportion of CD8 (+) T cell and M1 macrophages. ConclusionVISTA was remarkably correlated with a favorable prognosis and high immune infiltration in patients with TNBC.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Natural Killer Cells: Development, Maturation, and Clinical Utilization
    Abel, Alex M.
    Yang, Chao
    Thakar, Monica S.
    Malarkannan, Subramaniam
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [2] Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
    Ali, H. R.
    Provenzano, E.
    Dawson, S-J
    Blows, F. M.
    Liu, B.
    Shah, M.
    Earl, H. M.
    Poole, C. J.
    Hiller, L.
    Dunn, J. A.
    Bowden, S. J.
    Twelves, C.
    Bartlett, J. M. S.
    Mahmoud, S. M. A.
    Rakha, E.
    Ellis, I. O.
    Liu, S.
    Gao, D.
    Nielsen, T. O.
    Pharoah, P. D. P.
    Caldas, C.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (08) : 1536 - 1543
  • [3] xCell: digitally portraying the tissue cellular heterogeneity landscape
    Aran, Dvir
    Hu, Zicheng
    Butte, Atul J.
    [J]. GENOME BIOLOGY, 2017, 18
  • [4] VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
    Cao, Xi
    Ren, Xinyu
    Zhou, Yidong
    Mao, Feng
    Lin, Yan
    Wu, Huanwen
    Sun, Qiang
    [J]. FRONTIERS IN ONCOLOGY, 2021, 10
  • [5] Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
    Deng, Jie
    Li, Jiannan
    Sarde, Aurelien
    Lines, J. Louise
    Lee, Yu-Chi
    Qian, David C.
    Pechenick, Dov A.
    Manivanh, Richard
    Le Mercier, Isabelle
    Lowrey, Christopher H.
    Varn, Frederick S.
    Cheng, Chao
    Leib, David A.
    Noelle, Randolph J.
    Mabaera, Rodwell
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (07) : 1079 - 1090
  • [6] The immune contexture in cancer prognosis and treatment
    Fridman, Wolf H.
    Zitvogel, Laurence
    Sautes-Fridman, Catherine
    Kroemer, Guido
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (12) : 717 - 734
  • [7] VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    Gao, Jianjun
    Ward, John F.
    Pettaway, Curtis A.
    Shi, Lewis Z.
    Subudhi, Sumit K.
    Vence, Luis M.
    Zhao, Hao
    Chen, Jianfeng
    Chen, Hong
    Efstathiou, Eleni
    Troncoso, Patricia
    Allison, James P.
    Logothetis, Christopher J.
    Wistuba, Ignacio I.
    Sepulveda, Manuel A.
    Sun, Jingjing
    Wargo, Jennifer
    Blando, Jorge
    Sharma, Padmanee
    [J]. NATURE MEDICINE, 2017, 23 (05) : 551 - +
  • [8] Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
    Haslam, Alyson
    Prasad, Vinay
    [J]. JAMA NETWORK OPEN, 2019, 2 (05)
  • [9] Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis
    He, Xin-Lin
    Zhou, Ying
    Lu, Huan-Zi
    Li, Qun-Xing
    Wang, Zhi
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer
    Hou, Zelin
    Pan, Yu
    Fei, Qinglin
    Lin, Yali
    Zhou, Yuanyuan
    Liu, Ying
    Guan, Hongdan
    Yu, Xunbin
    Lin, Xianchao
    Lu, Fengchun
    Huang, Heguang
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (02) : 517 - 531